JPS6313989B2 - - Google Patents
Info
- Publication number
- JPS6313989B2 JPS6313989B2 JP61215196A JP21519686A JPS6313989B2 JP S6313989 B2 JPS6313989 B2 JP S6313989B2 JP 61215196 A JP61215196 A JP 61215196A JP 21519686 A JP21519686 A JP 21519686A JP S6313989 B2 JPS6313989 B2 JP S6313989B2
- Authority
- JP
- Japan
- Prior art keywords
- acetylcarnosine
- aluminum salt
- aluminum
- ulcer
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 N-acetylcarnosine aluminum salt Chemical class 0.000 claims description 23
- 108700016464 N-acetylcarnosine Proteins 0.000 claims description 22
- 229910052782 aluminium Inorganic materials 0.000 claims description 5
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
- 208000025865 Ulcer Diseases 0.000 description 14
- 231100000397 ulcer Toxicity 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 208000008469 Peptic Ulcer Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 210000001187 pylorus Anatomy 0.000 description 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004455 differential thermal analysis Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- JPUHCPXFQIXLMW-UHFFFAOYSA-N aluminium triethoxide Chemical compound CCO[Al](OCC)OCC JPUHCPXFQIXLMW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 229940067131 aspirin 100 mg Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000000138 effect on histamine Effects 0.000 description 1
- 230000001814 effect on stress Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940082061 indomethacin 25 mg Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
〔産業上の利用分野〕
本発明は新規なＮ−アセチルカルノシンアルミ
ニウム塩およびその製造法に関する。
〔従来の技術及びその問題点〕
本発明のＮ−アセチルカルノシンアルミニウム
塩はＮ−〔β−（N′−アセチルアミノ）プロピオ
ニル〕ヒスチジンモノアルミニウムなる化学名を
有し、次の式（）で表わされる。
近年、消化性潰瘍患者は増加する傾向にあり、
その治療剤の開発のために種々の研究が行われて
いる。また、消化性潰瘍は再発、再燃を繰返す事
が多いとされているが、現在それらを顕著に抑え
る抗潰瘍剤は知られておらず、かかる薬物の開発
が強く望まれている。
〔問題を解決するための手段〕
そこで、本発明者らは、多くの化合物を合成
し、その薬理効果を検討したところ、上記式
（）で表わされるＮ−アセチルカルノシンアル
ミニウム塩が、極めて優れた消化性潰瘍治療効果
を有すると共に毒性が低く極めて優れたものであ
ることを見出し、本発明を完成した。
従つて、本発明の目的な新規なＮ−アセチルカ
ルノシンアルミニウム塩を提供せんとするにあ
る。
本発明の他の目的は、Ｎ−アセチルカルノシン
アルミニウム塩を製造するための新規な方法を提
供せんとするにある。
本発明のＮ−アセチルカルノシンアルミニウム
塩は、例えばＮ−アセチルカルノシンにアルミニ
ウムアルコキシドを反応せしめることにより製造
される。
アルミニウムアルコキシドとしては、アルミニ
ウムメトキシド、アルミニウムエトキシド、アル
ミニウムイソプロポキシド、アルミニウムｔ−ブ
トキシド、アルミニウムシクロヘキシルオキシド
等が使用される。このアルミニウムアルコキシド
が水酸化アルミニウム又はその重合体等の不純物
を含んでいる場合には、蒸留、溶媒抽出等によつ
て不純物を除去したものを使用するのが好まし
い。
反応は適当な溶媒中、室温ないし80℃の温度で
行うのが好ましい。溶媒としては水又はメタノー
ル、エタノール、イソプロパノール、ブタノール
等の有機溶媒あるいはこれらの混和物が使用され
る。反応後、反応液から溶媒及び副生するアルコ
ール類を除去すれば目的物（）が単離される。
〔作用〕
次に、本発明のＮ−アセチルカルノシンアルミ
ニウム塩について、その消化性潰瘍治療効果及び
毒性を試験した結果を示す。尚比較対照化合物と
して、従来抗潰瘍作用を有すことが知られている
カルノシン、Ｌ−グルタミン、蔗糖硫酸エステル
アルミニウム塩を用いた。
実験 １
幽門結紮潰瘍に対する作用：
体重210〜230ｇのドンリユウ系雄ラツトを１群
10匹とした。Shayら（Gastroenterology、５、
43〜61、1945）の方法に従い48時間絶食し、エー
テル麻酔下に幽門部を結紮する。14時間絶食、絶
水下に放置し、胃をとり出し胃液を採取後、前胃
部に発生する潰瘍の面積（mm2）を解剖顕微鏡下
（10倍）にて計測し潰瘍指数として表わした。薬
物は幽門結紮直後に経口的に投与した。
結果を表１に示す。
[Industrial Field of Application] The present invention relates to a novel N-acetylcarnosine aluminum salt and a method for producing the same. [Prior art and its problems] The N-acetylcarnosine aluminum salt of the present invention has a chemical name of N-[β-(N'-acetylamino)propionyl]histidine monoaluminum and is represented by the following formula (). It can be done. In recent years, the number of peptic ulcer patients has been increasing.
Various studies are being conducted for the development of therapeutic agents. Furthermore, although it is said that peptic ulcers often have repeated recurrences and relapses, there are currently no known anti-ulcer agents that can significantly suppress these recurrences, and the development of such drugs is strongly desired. [Means for solving the problem] Therefore, the present inventors synthesized many compounds and examined their pharmacological effects, and found that N-acetylcarnosine aluminum salt represented by the above formula () was extremely excellent. The present invention was completed based on the discovery that it has an excellent therapeutic effect on peptic ulcers and has low toxicity. Therefore, it is an object of the present invention to provide a novel N-acetylcarnosine aluminum salt. Another object of the present invention is to provide a new method for producing N-acetylcarnosine aluminum salt. The N-acetylcarnosine aluminum salt of the present invention is produced, for example, by reacting N-acetylcarnosine with an aluminum alkoxide. As the aluminum alkoxide, aluminum methoxide, aluminum ethoxide, aluminum isopropoxide, aluminum t-butoxide, aluminum cyclohexyl oxide, etc. are used. When this aluminum alkoxide contains impurities such as aluminum hydroxide or its polymer, it is preferable to use one from which the impurities have been removed by distillation, solvent extraction, etc. The reaction is preferably carried out in a suitable solvent at a temperature of room temperature to 80°C. As the solvent, water, an organic solvent such as methanol, ethanol, isopropanol, butanol, or a mixture thereof is used. After the reaction, the target product () can be isolated by removing the solvent and by-product alcohols from the reaction solution. [Effect] Next, the results of testing the peptic ulcer therapeutic effect and toxicity of the N-acetylcarnosine aluminum salt of the present invention will be shown. As comparative compounds, carnosine, L-glutamine, and sucrose sulfate aluminum salt, which are conventionally known to have anti-ulcer effects, were used. Experiment 1 Effect on pylorus ligation ulcer: 1 group of male rats weighing 210-230g
The number was 10. Shay et al. (Gastroenterology, 5,
43-61, 1945), fast for 48 hours, and ligate the pylorus under ether anesthesia. After 14 hours of fasting and water deprivation, the stomach was removed and gastric juice was collected.The area (mm 2 ) of ulcers occurring in the forestomach was measured under a dissecting microscope (10x magnification) and expressed as an ulcer index. . Drugs were administered orally immediately after pylorus ligation. The results are shown in Table 1.
【表】
実験 ２
ストレス潰瘍に対する作用：
体重240〜260ｇのドンリユウ系雄ラツトを１群
10匹とし、高木ら（Jap.J.Pharmac.18(9)、９〜
18、1968）の拘束ストレスケージに入れ23℃の水
槽に胸部剣状突起まで水浸してストレスを負荷し
た。７時間後に水槽より引き揚げ、直ちに撲殺し
て胃を取り出した。１％ホルマリン液を胃内に注
入すると同時に１％ホルマリン液中に10分間浸し
た後胃を大彎に沿つて切開し、腺胃部に発生して
いる粘膜潰瘍の長さ（mm）を計測し潰瘍指数とし
て表した。薬物はストレス負荷10分前に経口投与
した。
結果を表２に示す。[Table] Experiment 2 Effect on stress ulcers: One group of male rats weighing 240-260 g.
Takagi et al. (Jap.J.Pharmac.18(9), 9-
18, 1968) and placed in a restrained stress cage and immersed in water up to the xiphoid process in a 23°C water tank to apply stress. Seven hours later, the fish was removed from the tank, immediately beaten to death, and its stomach was removed. Inject 1% formalin solution into the stomach and at the same time immerse it in 1% formalin solution for 10 minutes, then incise the stomach along the greater curvature and measure the length (mm) of the mucosal ulcer occurring in the glandular stomach area. It was expressed as an ulcer index. Drugs were orally administered 10 minutes before stress loading. The results are shown in Table 2.
【表】
実験 ３
アスピリン潰瘍に対する作用：
体重220〜230ｇのドンリユウ系雄ラツトを１群
10匹とし、岡部ら（Jap.J.Pharmac.24、357〜
361、1974）の方法に従い24時間絶食後、エーテ
ル麻酔下に幽門部を結紮する。腹部を閉じた後、
アスピリン100mg／Kgを経口投与する。７時間後
にエーテル麻酔下に胃を摘出し胃液を採取後、１
％ホルマリン処理し、腺胃部に発生する潰瘍の長
さ（mm）を測定し、１匹当りの合計を潰瘍指数と
した。被検薬物は幽門結紮直後経口的に投与し
た。
結果を表３に示す。[Table] Experiment 3 Effect on aspirin ulcers: One group of male rats weighing 220-230 g.
Okabe et al. (Jap.J.Pharmac.24, 357~
After fasting for 24 hours, the pylorus is ligated under ether anesthesia according to the method of 361, 1974). After closing the abdomen,
Administer aspirin 100mg/Kg orally. After 7 hours, the stomach was removed under ether anesthesia and gastric juice was collected.
% formalin treatment, the length (mm) of ulcers occurring in the glandular stomach was measured, and the total per animal was taken as the ulcer index. The test drug was orally administered immediately after pylorus ligation. The results are shown in Table 3.
【表】
実験 ４
インドメタシン潰瘍に対する作用：
体重200〜215ｇのドンリユウ系雄ラツトを１群
10匹とし、24時間絶食後インドメタシン25mg／Kg
を皮下に投与した。７時間後に動物をエーテル致
死せしめ、胃を摘出し１％ホルマリン液中に10分
間浸した。半固定された胃を大彎に沿つて切開し
粘膜部に発生する潰瘍の長さ（mm）を計測し潰瘍
指数として表わした。薬物はインドメタシン投与
10分前に経口投与した。
結果を表４に示す。[Table] Experiment 4 Effect of indomethacin on ulcers: 1 group of male rats weighing 200 to 215 g.
10 animals, indomethacin 25mg/Kg after 24 hours fasting
was administered subcutaneously. After 7 hours, the animals were sacrificed with ether, and the stomachs were removed and immersed in 1% formalin for 10 minutes. The semi-fixed stomach was incised along the greater curvature, and the length (mm) of ulcers occurring in the mucosal area was measured and expressed as an ulcer index. The drug is indomethacin administration.
Administered orally 10 minutes prior. The results are shown in Table 4.
【表】
実験 ５
ヒスタミン潰瘍に対する作用：
体重210〜230ｇのドンリユウ系雄ラツトを１群
10匹とし、48時間絶食後リン酸ヒスタミン300
mg／Kgを腹腔内に投与した。４時間後に動物をエ
ーテル致死せしめ、胃を摘出し１％ホルマリン液
中に10分間浸した。半固定された胃を大彎に沿つ
て切開し粘膜部に発生する潰瘍の長さ（mm）を計
測し潰瘍指数として表した。薬物はヒスタミン投
与の10分前に経口投与した。
結果を表５に示す。[Table] Experiment 5 Effect on histamine ulcer: One group of male rats weighing 210 to 230 g.
10 animals, histamine phosphate 300mg after 48 hours fasting
mg/Kg was administered intraperitoneally. After 4 hours, the animals were sacrificed with ether, and the stomachs were removed and immersed in 1% formalin for 10 minutes. The semi-fixed stomach was incised along the greater curvature, and the length (mm) of ulcers occurring in the mucosal area was measured and expressed as an ulcer index. Drugs were administered orally 10 minutes before histamine administration. The results are shown in Table 5.
【表】【table】
【表】
実験 ６
急性毒性試験：
体重150〜200ｇのウイスター系雌雄ラツトを１
群10匹としてＮ−アセチルカルノシンアルミニウ
ム塩を経口投与した。観察期間は７日間とした。
結果を表６に示す。[Table] Experiment 6 Acute toxicity test: One male and female Wistar rat weighing 150 to 200 g.
N-acetylcarnosine aluminum salt was orally administered to a group of 10 animals. The observation period was 7 days. The results are shown in Table 6.
以上の試験結果から明らかなように、本発明の
Ｎ−アセチルカルノシンアルミニウム塩は安全性
の高い優れた消化性潰瘍治療剤として使用でき
る。Ｎ−アセチルカルノシンアルミニウム塩は、
経口、非経口の何れにおいても投与でき、経口投
与用の剤型としては、例えば錠剤、カプセル剤、
散剤、顆粒剤およびシロツプ剤等があげられ、非
経口投与用の剤型としては注射剤等があげられ
る。
投与量は、成人に対し500〜5000mg／日である
が、年令、症状等により多少増減させることがで
きる。
〔実施例〕
次に実施例及び参考例を挙げて説明する。
実施例 １
5.36ｇのＮ−アセチルカルノシンを100mlの水
に溶解し、これを加温し、約40℃の温溶液とし、
激しく撹拌しながら4.08ｇのアルミニウムイソプ
ロポキサイドを含む90mlのイソプロピルアルコー
ル溶液を徐々に滴下した。滴下終了後40℃で10分
間撹拌した後不溶物を別し、減圧下で溶媒を留
去した。得られた油状残渣にイソプロピルアルコ
ールを加え固化させた。固体を粉末状として後
集し、イソプロピルアルコールで充分に洗浄し
た。減圧下60℃で乾燥することにより融点210℃
（分解点）の無色粉末6.5ｇ（定量的）を得た。
IRνKBr naxcm-1：3400（OH）、1660〜1550（Ｃ＝Ｏ）
NMR（D2O）δ：2.00（3H、ｓ、COCH3 ）
2.55（2H、ｍ、CH2CH2 NHAc）
3.40（4H、ｍ、COCH2 CH2とＣH2 −CH）
4.20（1H、ｍ、メチルプロトン）
7.30、8.50（1H×２、ｓ×２、イミダゾール環
プロトン）
元素分析 C11H17N4O6Alとして
計算値（％） Ｃ：40.25 Ｈ：5.22 Ｎ：17.07
分析値（％） Ｃ：40.18 Ｈ：5.58 Ｎ：16.76
上で得られた粉末５ｇを水30mlに溶解し、これ
を80℃で噴霧乾燥して、無色粉末のＮ−アセチル
カルノシンアルミニウム塩4.8ｇを得た。
斯くして得られたＮ−アセチルカルノシンアル
ミニウム塩の物性は次のとおりである。
赤外線吸収スペクトル：第１図
示差熱分析図：第２図
NMR（D2O）δ：1.88（3H、ｓ、−COCH3 ）
2.43（2H、ｍ、−CH2CH2 NHCOCH3）
3.28（4H、ｍ、−COCH2 CH2N、−ＣH2
CHCOO）
4.09（1H、ｍ、メチルプロトン）
7.05、8.10（1H×２、ｓ×２、イミダゾール環
プロトン）
元素分析 C11H15N4O4Al（OH）2として
計算値(%)Ｃ ：40.25 Ｈ：5.22 Ｎ：17.07
Al： 8.22
分析値(%)Ｃ ：40.10 Ｈ：5.41 Ｎ：16.77
Al： 8.01
実施例 ２
4.5ｇのＮ−アセチルカルノシンを30mlの水に
溶解し、これを約60℃に加温し、激しく撹拌しな
がら3.75ｇのアルミニウムイソプロポキシドを含
む25mlのイソプロピルアルコール溶液を徐々に滴
下した。滴下終了後60℃で４時間撹拌した後、減
圧下イソプロピルアルコールを留去した。残留し
た水溶液から不溶物を去し、水溶液を80℃で噴
霧乾燥して無色粉末のＮ−アセチルカルノシンア
ルミニウム塩5.1ｇ（定量的）を得た。このもの
は実施例１で得られたものと同一であつた。
参考例 １
製剤例（顆粒剤）
１ｇ中、下記成分を含有する。
Ｎ−アセチルカルノシンアルミニウム塩 200mg
乳 糖 400mg
コーンスターチ 400mg
As is clear from the above test results, the N-acetylcarnosine aluminum salt of the present invention can be used as a highly safe and excellent therapeutic agent for peptic ulcers. N-acetylcarnosine aluminum salt is
It can be administered either orally or parenterally, and dosage forms for oral administration include, for example, tablets, capsules,
Examples include powders, granules and syrups, and dosage forms for parenteral administration include injections. The dosage for adults is 500 to 5000 mg/day, but it can be increased or decreased depending on age, symptoms, etc. [Examples] Next, examples and reference examples will be given and explained. Example 1 5.36g of N-acetylcarnosine was dissolved in 100ml of water and heated to form a hot solution at about 40°C,
While stirring vigorously, 90 ml of isopropyl alcohol solution containing 4.08 g of aluminum isopropoxide was gradually added dropwise. After the dropwise addition was completed, the mixture was stirred at 40°C for 10 minutes, then insoluble matter was separated, and the solvent was distilled off under reduced pressure. Isopropyl alcohol was added to the obtained oily residue to solidify it. The solid was collected as a powder and thoroughly washed with isopropyl alcohol. Melting point 210℃ by drying at 60℃ under reduced pressure
(decomposition point) 6.5 g (quantitative) of colorless powder was obtained. IRν KBr nax cm -1 : 3400 (OH), 1660-1550 (C=O) NMR (D 2 O) δ: 2.00 (3H, s, COC H 3 ) 2.55 (2H, m, CH 2 C H 2 NHAc ) 3.40 (4H, m, COC H 2 CH 2 and C H 2 -CH) 4.20 (1H, m, methyl proton) 7.30, 8.50 (1H x 2, s x 2, imidazole ring proton) Elemental analysis C 11 H 17 As N 4 O 6 Al Calculated value (%) C: 40.25 H: 5.22 N: 17.07 Analytical value (%) C: 40.18 H: 5.58 N: 16.76 Dissolve 5 g of the powder obtained above in 30 ml of water, and Spray drying at 80°C gave 4.8 g of N-acetylcarnosine aluminum salt as a colorless powder. The physical properties of the N-acetylcarnosine aluminum salt thus obtained are as follows. Infrared absorption spectrum: Figure 1 Differential thermal analysis: Figure 2 NMR (D 2 O) δ: 1.88 (3H, s, -COC H 3 ) 2.43 (2H, m, -CH 2 CH 2 NHCOCH 3 ) 3.28 (4H, m, -COC H 2 CH 2 N, -C H 2
CHCOO) 4.09 (1H, m, methyl proton) 7.05, 8.10 (1H x 2, s x 2, imidazole ring proton) Elemental analysis C 11 H 15 N 4 O 4 Al (OH) 2 Calculated value (%) C: 40.25 H: 5.22 N: 17.07 Al: 8.22 Analysis value (%) C: 40.10 H: 5.41 N: 16.77 Al: 8.01 Example 2 4.5 g of N-acetylcarnosine was dissolved in 30 ml of water, and the solution was heated to about 60°C. 25 ml of isopropyl alcohol solution containing 3.75 g of aluminum isopropoxide was gradually added dropwise while stirring vigorously. After the dropwise addition was completed, the mixture was stirred at 60°C for 4 hours, and then the isopropyl alcohol was distilled off under reduced pressure. Insoluble matter was removed from the remaining aqueous solution, and the aqueous solution was spray-dried at 80°C to obtain 5.1 g (quantitative) of N-acetylcarnosine aluminum salt as a colorless powder. This was the same as that obtained in Example 1. Reference example 1 Formulation example (granule) 1 g contains the following ingredients. N-acetylcarnosine aluminum salt 200mg Lactose 400mg Cornstarch 400mg
第１図はＮ−アセチルカルノシンアルミニウム
塩の赤外線吸収スペクトル、第２図はＮ−アセチ
ルカルノシンアルミニウム塩の示差熱分析図であ
る。
FIG. 1 is an infrared absorption spectrum of N-acetylcarnosine aluminum salt, and FIG. 2 is a differential thermal analysis diagram of N-acetylcarnosine aluminum salt.
Claims (1)
ム塩。 ２ Ｎ−アセチルカルノシンにアルミニウムアル
コキシドを反応せしめることを特徴とする次の式
（）、 で表わされるＮ−アセチルカルノシンアルミニウ
ム塩の製造法。[Claims] First-order equation (), N-acetylcarnosine aluminum salt represented by: 2 The following formula (), which is characterized by reacting aluminum alkoxide with N-acetylcarnosine, A method for producing N-acetylcarnosine aluminum salt represented by
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61215196A JPS6284063A (en) | 1986-09-12 | 1986-09-12 | N-acetylcarnosine aluminum salt and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61215196A JPS6284063A (en) | 1986-09-12 | 1986-09-12 | N-acetylcarnosine aluminum salt and its preparation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11671779A Division JPS5640614A (en) | 1979-09-13 | 1979-09-13 | Novel type remedy for peptic ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6284063A JPS6284063A (en) | 1987-04-17 |
| JPS6313989B2 true JPS6313989B2 (en) | 1988-03-29 |
Family
ID=16668276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61215196A Granted JPS6284063A (en) | 1986-09-12 | 1986-09-12 | N-acetylcarnosine aluminum salt and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6284063A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5655378A (en) * | 1979-10-12 | 1981-05-15 | Nippon Chemiphar Co Ltd | N-(b-(n'-acylamino)propionyl)histidine aluminum salt and its preparation |
-
1986
- 1986-09-12 JP JP61215196A patent/JPS6284063A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6284063A (en) | 1987-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU1771472C (en) | Method for production of 2-cyano-(4-tret-alkyl phenyl)-3-oxibut-2-enamide | |
| JPS6229566A (en) | Novel guanidinomthylbenzoic acid derivative | |
| JPS6312844B2 (en) | ||
| CA1067501A (en) | Process for preparing substituted guanidines | |
| DE2523103A1 (en) | NEW PROPARGYL-2-PHENYLAMINO-IMIDAZOLINE- (2), THEIR ACID-ADDITIONAL SALTS, THESE MEDICINAL PRODUCTS AND METHOD FOR MANUFACTURING THE SAME | |
| JPS6313989B2 (en) | ||
| JPS6315275B2 (en) | ||
| JPS5879950A (en) | Novel derivatives of 4-phenyl-4-oxo-2-butenoic acid and their salts, manufacture, use as drug and composition containing them | |
| US4473583A (en) | Compositions containing certain derivatives of 4-phenyl-4-oxobuten-2-oic acid and methods of treatment using them | |
| AT391316B (en) | NEW THIENYLOXY ALKYLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
| JP5550696B2 (en) | Novel crystals of substituted phenylalkanoic acid esters and production method thereof | |
| JPS6316382B2 (en) | ||
| DE69025967T2 (en) | Aryl or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid derivatives, for the treatment of diseases caused by interleukin-1 | |
| JPS6241234B2 (en) | ||
| CA1294976C (en) | 4-phenyl 4-oxo 2-butenoic acid derivatives, process for preparing such, their use as medications and preparations containing such derivatives | |
| JPH0135829B2 (en) | ||
| JPS6251951B2 (en) | ||
| JPS6315276B2 (en) | ||
| US4126625A (en) | Certain 5-substituted-3-methyl-2-benzofuran acetic acids | |
| CN113402390B (en) | Aspirin medicine eutectic and preparation method and application thereof | |
| JPH0323526B2 (en) | ||
| JPS6350352B2 (en) | ||
| DE2527352A1 (en) | ALKINE DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION | |
| JPS6312843B2 (en) | ||
| US4172145A (en) | Benzo(b)furylacetic acid derivatives to reduce inflammation |